LEXICON PHARMACEUTICALS INC (LXRX) Stock Price, Quote, News and Overview
NASDAQ:LXRX - Nasdaq - US5288723027 - Common Stock - Currency: USD
LXRX Quote, Performance and Key Statistics
0.6136
+0.04 (+7.65%)
The current stock price of LXRX is 0.6136 USD. In the past month the price decreased by -8.66%. In the past year, price decreased by -62.12%.
LXRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.7 | 321.60B | ||
| AMGN | AMGEN INC | 13.07 | 145.89B | ||
| GILD | GILEAD SCIENCES INC | 13.92 | 134.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.65 | 65.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.06B | ||
| ARGX | ARGENX SE - ADR | 99.65 | 35.72B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.49B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.54B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.87B | ||
| BIIB | BIOGEN INC | 8.02 | 18.58B |
Related stock screener links
About LXRX
Company Profile
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 103 full-time employees. The company went IPO on 2000-04-07. The firm is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The firm pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The firm is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The firm is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Company Info
LEXICON PHARMACEUTICALS INC
2445 Technology Forest Blvd, 11Th Floor
The Woodlands TEXAS 77381 US
CEO: Lonnel Coats
Employees: 103
Phone: 12818633000
LEXICON PHARMACEUTICALS INC / LXRX FAQ
What is the stock price of LEXICON PHARMACEUTICALS INC today?
The current stock price of LXRX is 0.6136 USD. The price increased by 7.65% in the last trading session.
What is the ticker symbol for LEXICON PHARMACEUTICALS INC stock?
The exchange symbol of LEXICON PHARMACEUTICALS INC is LXRX and it is listed on the Nasdaq exchange.
On which exchange is LXRX stock listed?
LXRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LEXICON PHARMACEUTICALS INC stock?
11 analysts have analysed LXRX and the average price target is 2.65 USD. This implies a price increase of 332.2% is expected in the next year compared to the current price of 0.6136. Check the LEXICON PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LEXICON PHARMACEUTICALS INC worth?
LEXICON PHARMACEUTICALS INC (LXRX) has a market capitalization of 222.85M USD. This makes LXRX a Micro Cap stock.
How many employees does LEXICON PHARMACEUTICALS INC have?
LEXICON PHARMACEUTICALS INC (LXRX) currently has 103 employees.
What are the support and resistance levels for LEXICON PHARMACEUTICALS INC (LXRX) stock?
LEXICON PHARMACEUTICALS INC (LXRX) has a support level at 0.55 and a resistance level at 0.62. Check the full technical report for a detailed analysis of LXRX support and resistance levels.
Is LEXICON PHARMACEUTICALS INC (LXRX) expected to grow?
The Revenue of LEXICON PHARMACEUTICALS INC (LXRX) is expected to decline by -13.39% in the next year. Check the estimates tab for more information on the LXRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LEXICON PHARMACEUTICALS INC (LXRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LXRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LXRX, evaluating the profitability, health, valuation and growth aspects
- LEXICON PHARMACEUTICALS INC (LXRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LEXICON PHARMACEUTICALS INC (LXRX) Sales and EPS estimates to see what analysts future expectations are.
- LEXICON PHARMACEUTICALS INC (LXRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LEXICON PHARMACEUTICALS INC (LXRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- LEXICON PHARMACEUTICALS INC (LXRX) Stock Chart to make your own analysis
- LEXICON PHARMACEUTICALS INC (LXRX) Latest news and press-releases to stay up to date.
Does LEXICON PHARMACEUTICALS INC (LXRX) stock pay dividends?
LXRX does not pay a dividend.
When does LEXICON PHARMACEUTICALS INC (LXRX) report earnings?
LEXICON PHARMACEUTICALS INC (LXRX) will report earnings on 2025-07-30, before the market open.
What is the Price/Earnings (PE) ratio of LEXICON PHARMACEUTICALS INC (LXRX)?
LEXICON PHARMACEUTICALS INC (LXRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.51).
What is the Short Interest ratio of LEXICON PHARMACEUTICALS INC (LXRX) stock?
The outstanding short interest for LEXICON PHARMACEUTICALS INC (LXRX) is 10.38% of its float. Check the ownership tab for more information on the LXRX short interest.
LXRX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to LXRX. When comparing the yearly performance of all stocks, LXRX is a bad performer in the overall market: 89.98% of all stocks are doing better.
LXRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LXRX. Both the profitability and financial health of LXRX have multiple concerns.
LXRX Financial Highlights
Over the last trailing twelve months LXRX reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS increased by 38.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.15% | ||
| ROE | -137.31% | ||
| Debt/Equity | 0.69 |
LXRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to LXRX. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 45.81% and a revenue growth -13.39% for LXRX